Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors

Series A financing led by Westlake Village BioPartners with participation from Corner Ventures, Alexandria Venture Investments, and Caltech Phase 1 data on lead product candidate in metastatic HER2-negative breast cancer, to be presented at San Antonio Breast Cancer Symposium THOUSAND…